JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis

• Published in: Blood cancer journal (New York) 2021-12, Vol.11 (12), p.199-199, Article 199
• Main Authors: Guglielmelli, Paola, Loscocco, Giuseppe G., Mannarelli, Carmela, Rossi, Elena, Mannelli, Francesco, Ramundo, Francesco, Coltro, Giacomo, Betti, Silvia, Maccari, Chiara, Ceglie, Sara, Chiusolo, Patrizia, Paoli, Chiara, Barbui, Tiziano, Tefferi, Ayalew, De Stefano, Valerio, Vannucchi, Alessandro M.
• Format: Article
• Language: English
• Subjects: 631/208/68; 631/67/1990/2331; Adult; Aged; Aged, 80 and over; Biomedical and Life Sciences; Biomedicine; Blood cancer; Cancer Research; Female; Gene Frequency; Hematology; Humans; Janus Kinase 2 - genetics; Male; Middle Aged; Oncology; Point Mutation; Polycythemia Vera - complications; Polycythemia Vera - genetics; Retrospective Studies; Risk Factors; Thrombosis; Venous Thrombosis - etiology; Venous Thrombosis - genetics; Young Adult
• ISSN: 2044-5385; 2044-5385
• DOI: 10.1038/s41408-021-00581-6

Arterial (AT) and venous (VT) thrombotic events are the most common complications in patients with polycythemia vera (PV) and are the leading causes of morbidity and mortality. In this regard, the impact of JAK2 V617F variant allele frequency (VAF) is still debated. The purpose of the current study was to analyze the impact of JAK2 V617F VAF in the context of other established risk factors for thrombosis in a total of 865 2016 WHO-defined PV patients utilizing two independent cohorts: University of Florence ( n  = 576) as a training cohort and Policlinico Gemelli, Catholic University, Rome ( n  = 289) as a validation cohort. In the training cohort VT free-survival was significantly shorter in the presence of a JAK2 V617F VAF > 50% (HR 4; p   50% (HR 3.8, p  = 0.001) and previous VT (HR 2.2; p  = 0.04) as independent risk factors for future VT whereas diabetes (HR 2.4; p  = 0.02), hyperlipidemia (HR 2.3; p  = 0.01) and previous AT (HR 2; p  = 0.04) were independent risk factors for future AT. Similarly, JAK2 V617F VAF > 50% (HR 2.4; p  = 0.01) and previous VT (HR 2.8; p  = 0.005) were confirmed as independent predictors of future VT in the validation cohort. Impact of JAK2 V617F VAF > 50% on VT was particularly significant in conventional low-risk patients, both in Florence (HR 10.6, p  = 0.005) and Rome cohort (HR 4; p  = 0.02). In conclusion, we identified JAK2 V617F VAF > 50% as an independent strong predictor of VT, supporting that AT and VT are different entities which might require distinct management.